Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788a.
No abstract available

Publication types

  • Published Erratum